New York, August 09, 2024 - PRISM MarketView - Organigram Holdings Inc. (OGI) a leading licensed cannabis producer, announced the preliminary results of its groundbreaking clinical pharmacokinetic (PK) study, conducted through the Product Development Collaboration (PDC), on its latest innovation—nanoemulsion technology. This patent-pending technology, branded as FAST™ (Fast Acting Soluble Technology), marks the first innovation to be commercialized by Organigram, leveraging the work done at the PDC, a “Center of Excellence” dedicated to creating next-generation cannabis products.
The clinical study, completed in January 2024, has undergone data review, with the final report anticipated for publication in October 2024.
Early findings from the study suggest significant technological advancements, including:
- Faster onset: The effects of cannabis were observed to take effect up to 50% faster in certain ingestible formats compared to traditional products used as controls.
- Improved bioavailability: Cannabinoid delivery at peak levels was up to double that of the control group.
- More predictable duration: Initial indicators suggest a more consistent duration of effects, which could lead to the development of future claims regarding offset timing, pending further studies.
“We are thrilled with the results of this study. Our patent-pending FAST™ nanoemulsion technology has the potential to revolutionize how consumers experience cannabis, offering more precise control over dosage—a critical need in the ingestible product market. These advances highlight Organigram’s dedication to consumer-focused, science-driven innovation.”
Borna Zlamalik, SVP of Innovation and R&D
The study is considered one of the largest PK studies focused on adult-use recreational cannabis products. This comprehensive 19-day, in-clinic, eight-arm study, conducted by a leading third-party clinical research organization, assessed cannabinoid absorption across three key product formats to evaluate the effectiveness of this new delivery system.
Organigram plans to launch FAST™ in the fall of 2024, starting with gummies. Manufacturing scale-up trials for these gummies are currently underway at the company’s Winnipeg facility.
“We are confident that our investment in this technology will drive continued success in the edibles market, both domestically and internationally.”
Beena Goldenberg, CEO of Organigram
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities